Tredje AP fonden grew its stake in Colgate-Palmolive (NYSE:CL) by 81.7% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 103,885 shares of the company’s stock after purchasing an additional 46,703 shares during the quarter. Tredje AP fonden’s holdings in Colgate-Palmolive were worth $6,733,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. BlackRock Inc. lifted its holdings in Colgate-Palmolive by 3.0% during the first quarter. BlackRock Inc. now owns 53,953,299 shares of the company’s stock worth $3,867,373,000 after acquiring an additional 1,592,608 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Colgate-Palmolive by 11.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 32,560,326 shares of the company’s stock worth $2,110,235,000 after acquiring an additional 3,397,667 shares during the period. Bank of New York Mellon Corp lifted its holdings in Colgate-Palmolive by 8.6% during the second quarter. Bank of New York Mellon Corp now owns 20,135,385 shares of the company’s stock worth $1,304,974,000 after acquiring an additional 1,596,825 shares during the period. Wells Fargo & Company MN lifted its holdings in Colgate-Palmolive by 11.3% during the first quarter. Wells Fargo & Company MN now owns 9,886,686 shares of the company’s stock worth $708,678,000 after acquiring an additional 1,003,612 shares during the period. Finally, First Eagle Investment Management LLC lifted its holdings in Colgate-Palmolive by 45.7% during the first quarter. First Eagle Investment Management LLC now owns 7,830,595 shares of the company’s stock worth $561,297,000 after acquiring an additional 2,455,839 shares during the period. Institutional investors own 74.72% of the company’s stock.

A number of analysts recently commented on the company. Barclays set a $64.00 price target on Colgate-Palmolive and gave the stock a “hold” rating in a report on Monday, July 30th. Zacks Investment Research downgraded Colgate-Palmolive from a “hold” rating to a “sell” rating in a research report on Monday, July 2nd. UBS Group raised Colgate-Palmolive from a “neutral” rating to a “buy” rating and raised their target price for the stock from $70.00 to $75.00 in a research report on Wednesday, July 18th. Sanford C. Bernstein reissued a “market perform” rating and issued a $72.00 target price on shares of Colgate-Palmolive in a research report on Thursday, May 24th. Finally, Macquarie downgraded Colgate-Palmolive from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $74.00 to $65.00 in a research report on Monday, July 30th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $72.14.

In other news, insider Mukul Deoras sold 11,334 shares of Colgate-Palmolive stock in a transaction on Monday, August 13th. The stock was sold at an average price of $65.10, for a total value of $737,843.40. Following the completion of the transaction, the insider now directly owns 32,625 shares in the company, valued at $2,123,887.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Daniel B. Marsili sold 19,500 shares of Colgate-Palmolive stock in a transaction on Friday, June 15th. The shares were sold at an average price of $63.25, for a total value of $1,233,375.00. Following the completion of the transaction, the insider now owns 78,065 shares of the company’s stock, valued at $4,937,611.25. The disclosure for this sale can be found here. Over the last quarter, insiders sold 433,302 shares of company stock valued at $28,518,498. 1.02% of the stock is owned by company insiders.

NYSE:CL traded down $0.57 during trading hours on Tuesday, reaching $67.09. The stock had a trading volume of 46,879 shares, compared to its average volume of 3,799,863. The company has a debt-to-equity ratio of -34.49, a current ratio of 1.06 and a quick ratio of 0.74. Colgate-Palmolive has a 12-month low of $61.28 and a 12-month high of $77.91. The company has a market capitalization of $58.57 billion, a P/E ratio of 23.51, a P/E/G ratio of 3.02 and a beta of 0.75.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings results on Friday, July 27th. The company reported $0.77 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.77. The company had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.91 billion. Colgate-Palmolive had a return on equity of 2,494.79% and a net margin of 13.97%. The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.72 earnings per share. analysts anticipate that Colgate-Palmolive will post 3.02 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 15th. Stockholders of record on Wednesday, July 18th were given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 2.50%. The ex-dividend date of this dividend was Tuesday, July 17th. Colgate-Palmolive’s dividend payout ratio (DPR) is presently 58.54%.

Colgate-Palmolive declared that its Board of Directors has authorized a stock buyback plan on Monday, June 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 9% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its shares are undervalued.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, and other related products.

Featured Story: Understanding Relative Strength Index

Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.